Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun;10(3):101-8.
doi: 10.1016/j.drup.2007.04.001. Epub 2007 Jun 4.

The role of galectin-3 in cancer drug resistance

Affiliations
Review

The role of galectin-3 in cancer drug resistance

Tomoharu Fukumori et al. Drug Resist Updat. 2007 Jun.

Abstract

The galectins comprise a family of 14 members of beta-galactoside-binding proteins, characterized by their affinity for beta-galactosides and by a conserved sequence in the carbohydrate recognition domain that bind to the carbohydrate portion of cell surface glycoproteins or glycolipids. Galectin-3, a 31kDa gene product, is a multifunctional oncogenic protein which regulates cell growth, cell adhesion, cell proliferation, angiogenesis, and apoptosis. Recent studies have revealed that galectin-3 demonstrates anti-apoptotic effects which contribute to cell survival in several types of cancer cells. Intracellular galectin-3 in particular, which contains the NWGR anti-death motif of the Bcl-2 family, inhibits cell apoptosis induced by chemotherapeutic agent such as cisplatin and etoposide in some types of cancer cells. We have also reported that nuclear export of phosphorylated galectin-3 regulates its anti-apoptotic activity in response to chemotherapeutic drugs. Here, we will describe the role of galectin-3 as an anti-apoptotic factor in response to chemotherapeutic drugs and will discuss recent data on its molecular mechanism that contribute to drug resistance. We suggest that targeting galectin-3 could improve the efficacy of anticancer drug chemotherapy in several types of cancer.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structure and functional domain of galectin-3. Galectin-3 consists of three structural domains: (a) a NH2-terminal domain of 12 amino acid that contains a serine phosphorylation site; (b) a repeated collagen-like sequence rich in glycine, proline, and tyrosine; and (c) a COOH-terminal carbohydrate recognition domain (CRD) consisting 140 amino acid residues. The C-terminal domain includes the NWGR motif which is highly conserved in the BH1 domain of the Bcl-2 gene family including Bcl-2, Bcl-xL, and Bax.
Fig. 2
Fig. 2
Model for the regulation of apoptosis signaling pathways induced by anticancer drugs in galectin-3 expressing cells. Anticancer drugs can induce DNA damage, which causes phosphorylated galectin-3 to translocate from the nucleus to cytoplasm and regulates phosphorylation of Bad, Akt, and ERK resulting in stabilization of mitochondrial membrane integrity. The stabilization of the mitochondrial membrane prevents cytochrome c release and subsequent caspase activation, resulting in suppression of apoptosis and caused anticancer drug resistance.

Similar articles

Cited by

References

    1. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel anti-apoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res. 1997;57:5272–5276. - PubMed
    1. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J. Biol. Chem. 1994a;269:20807–20810. - PubMed
    1. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu F, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PW, Rini JM, Wang JL. Galectins: a family of animal beta-galactoside-binding lectins (letter) Cell. 1994b;76:597–598. - PubMed
    1. Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 1999;96:11329–11334. - PMC - PubMed
    1. Califice S, Castronovo V, Bracke M, Van Den Brule F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene. 2004;23:7527–7536. - PubMed